One of the immediate and ongoing neurological challenges posed by the COVID-19 pandemic is the management of patients who are undergoing immunotherapy for existing neuroimmunological disease. In this paper, recently published in Nature Reviews Neurology, the authors discuss the management of neuroimmunological disorders during the COVID-19 outbreak. They underline that COVID-19 affects the management of patients with neurological diseases in many ways and that the risks and benefits of immunoactive treatments in neuroimmunological disorders, and adjustments to these treatments, must be assessed. Moreover they concluded that new ways of remote monitoring and health care delivery are needed.
View Article: https://www.nature.com/articles/s41582-020-0368-9